Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Resources for healthcare professionals and patients

Use the information below to learn why TAKHZYRO is a proven preventive treatment for HAE and how to create effective HAE management plans for your patients. You'll also find resources you can share with your patients and their caregivers to help them start and stay on TAKHZYRO.

Understand the burden of HAE further

TAKHZYRO® Clinical Studies Brochure.

TAKHZYRO Clinical Studies Brochure

Learn about one of the largest
prevention studies in HAE with
the longest active treatment


HAE assessment patient questionnaire.

HAE Assessment Patient Questionnaire

Use this comprehensive list of
questions about the impact of
HAE on your patients to help
guide your initial assessment.


Read about a patient who chose effective prevention with TAKHZYRO

Case Study Brochure of TAKHZYRO® patient, Andrew.

Patient Case Study: Andrew

See how Andrew decided to start preventive treatment with TAKHZYRO after living for years with painful and debilitating HAE attacks.


Interested in enrolling your patients in the
Quick Start Program or OnePath®?

find application forms here

Access sample templates for appealing an insurance denial

explore templates

Resources for patients

Use the patient resources below to help explain TAKHZYRO to your patients and their caregivers.

TAKHZYRO® Conversation Starter.

TAKHZYRO Conversation Starter

See how your patients might start the conversation about TAKHZYRO.


TAKHZYRO® brochure.


Learn all about TAKHZYRO, from study results to dosing information and more.


TAKHZYRO® pediatric brochure.

Pediatric Brochure

Guide caregivers through helpful HAE information and useful tips on how they can support their loved ones taking TAKHZYRO.


TAKHZYRO® Getting Started brochure.

Getting Started with TAKHZYRO Brochure

Get an overview of what to expect upon starting treatment with TAKHZYRO.


TAKHZYRO® Instructions for Use.

TAKHZYRO Instructions for Use

Find out more about how to self-administer TAKHZYRO


Travel Medical Letter.

Travel Letter

Print this form and have your doctor fill it out so that you are always prepared to travel with TAKHZYRO.


Planning for an HAE attack brochure.

HAE Attack Plan

Fill this form out with your doctor and use it to explain HAE to others, including what steps to take in the event of an emergency.


Prescribing Information for TAKHZYRO®.

Prescribing Information

Explore the prescribing information, and ask your doctor any questions you might have about taking TAKHZYRO.


Encourage patient education

Woman sitting outside.

Your patients might benefit from seeing how other people are reimagining their lives with TAKHZYRO. Encourage them to explore our video gallery.

Patients can watch here

Some of your patients may need help remembering to take TAKHZYRO as you've prescribed. Encourage them to sign up for dosing reminders.

Patients can sign up here
US Hereditary Angioedema Association logo.

Your HAE patients can continue to explore resources and connect with support offered through the US Hereditary Angioedema Association (HAEA).


Looking for more resources to support your patients and your practice?

Sign up for emails

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2022. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022 Mar;77(3):979-990. 3. Cinryze. Prescribing information. Takeda Pharmaceuticals; 2021. 4. Haegarda. Prescribing information. CSL Behring LLC; 2020. 5. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2020.